pharma · Migraine · Narcolepsy
H. Lundbeck A/S
H. Lundbeck A/S clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Postboks 361, LYSAKER, Bærum 1326, NO, Valby, CN
- Employees
- 112
- Programs
- 17
- Drugs
- 14
- Patents
- 0
H. Lundbeck A/S projects
7 ClinicalTrials.gov programs sponsored by H. Lundbeck A/S.
H. Lundbeck A/S has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
19356A
H. Lundbeck A/S
Migraine
1 trial -
20432A
H. Lundbeck A/S
Multiple System Atrophy
1 trial -
Bifeprunox
H. Lundbeck A/S
Schizophrenia
1 trial -
Eptinezumab
H. Lundbeck A/S
Migraine
1 trial -
Lu AF35700
H. Lundbeck A/S
Treatment-resistant Schizophrenia
1 trial -
VYEPTI 100 mg concentrate for solution for infusion
H. Lundbeck A/S
Migraine
1 trial -
VYEPTI 100 mg concentrate for solution for infusion
H. Lundbeck A/S
Chronic migraine
1 trial
Frequently asked questions
How many clinical projects does H. Lundbeck A/S have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.